Abemaciclib pharmacology and interactions in the treatment of HR+/HER2− breast cancer: a critical review

• Main Authors: Federica Martorana (Author), Maria Vita Sanò (Author), Maria Rosaria Valerio (Author), Stefano Fogli (Author), Paolo Vigneri (Author), Romano Danesi (Author), Vittorio Gebbia (Author)
• Format: Book
• Published: SAGE Publishing, 2024-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abemaciclib (ABE) in combination with endocrine therapy represents the mainstay treatment for either endocrine-resistant metastatic or high-risk early-stage HR+/HER2− breast cancer patients. Hence, an adequate knowledge of this agent pharmacodynamic, pharmacokinetic, and of its drug-drug interaction...